Author Program NEW Create Narrative

Second Sight Medical Products, Inc. Stock Price

NasdaqCM:EYES Community·US$54.4m Market Cap

0 Narratives written by author
0 Comments on narratives written by author
0 Fair Values set on narratives written by author

Author Program NEW Create Narrative

EYES Share Price Performance

US$0

0.00 (0.00%)

US$0

0.00 (0.00%)

US$0

Wed, 12 Aug 26

Share Pricen/a

EYES Community Narratives

There are no narratives available yet.

Create Narrative

There are no community narratives available.

Trending Discussion

No trending discussion available.

Recently Updated Narratives

No recently updated narratives available.

Snowflake Analysis

Flawless balance sheet and slightly overvalued.

2 Risks

0 Rewards

View Full Analysis

Second Sight Medical Products, Inc. Key Details

Last Reported Earnings

Jun 30, 2022

Next Reporting Earnings

n/a

: -0.69
: 0%
: 0%
: 0%

View Full Analysis

About EYES

Founded: 1998
Employees: 15
CEO: Scott Dunbar
WebsiteView website: www.secondsight.com

Second Sight Medical Products, Inc. develops, manufactures, and markets implantable visual prosthetics that are intended to deliver artificial vision to blind individuals. It develops technologies to treat the population of sight-impaired individuals. The company offers the Orion Visual Cortical Prosthesis System, an implanted cortical stimulation device, which is intended to provide useful artificial vision to individuals who are blind due to various causes, including glaucoma, diabetic retinopathy, optic nerve injury or disease, and eye injury. The company was founded in 1998 and is headquartered in Sylmar, California.

Recent EYES News & Updates

Seeking Alpha • Aug 30

Second Sight, Nano Precision complete merger, renaming as Vivani Medical

Second Sight Medical Products (NASDAQ:EYES) said it completed its merger with Nano Precision Medical, and has changed its name to Vivani Medical Inc. The company's common stock will trade on Nasdaq under the symbol VANI. In February, Second Sight said it was merging with Nano in an all-stock deal, post which EYES shareholders would own ~23% of the combined company. In July, Second Sight shareholders approved the merger, name change, and a reverse stock split which took effect on Aug. 19. Second Sight said in an Aug. 30 press release that the company will operate under Nano CEO Adam Mendelsohn, and his leadership team. Nano develops miniaturized, subdermal drug implants using its proprietary NanoPortal technology to help in the long-term, near constant-rate delivery of a range of medicines to treat chronic diseases. Upon completion of the merger, the company has ~$55M in cash to advance the development of Vivani's portfolio, which includes lead asset NPM-119 (exenatide implant) into clinical-stage development to treat patients with type 2 diabetes and to identify and execute strategic options to advance clinical-stage Orion visual prosthetic device to treat people with blindness due to a wide range of underlying causes. EYES -5.28% to $4.13 premarket Aug. 30

Seeking Alpha • Aug 19

Second Sight Medical sheds ~17% after reverse stock split

Second Sight Medical Products, Inc. (NASDAQ:EYES), a maker of implantable visual prosthetics, dropped ~17% on Friday morning as its shares began trading on a split-adjusted basis following a 1-for-3 reverse stock split. In July, the company filed for an amendment to its Articles of Incorporation with the Secretary of State in California to implement a reverse stock split of its outstanding common stock. On Aug. 16, the company was notified that the California Secretary of State had accepted the amendment. The effective time of the amendment was 5:00 p.m. Pacific Time on Aug. 09, and the company shares started trading on a split-adjusted basis on Aug. 19, EYES said in a regulatory filing. The corporate action is in line with an amendment the company's shareholders approved in July for its Restated Articles of Incorporation. Commercial-stage biotech Palatin Technologies (PTN) also traded lower on Friday on its plans for a 1-for-25 reverse split.

Seeking Alpha • Jul 29

Second Sight stock rises as shareholders approve merger, name change, reverse stock split

Second Sight (NASDAQ:EYES) said its shareholders approved its merger with Nano Precision Medical, changing the company's name to Vivani Medical Inc. and a reverse stock split among other proposals, at the annual meeting. In February, Second Sight said it was merging with Nano in an all-stock deal, post which EYES shareholders would own ~23% of the combined company. The company said ~20.03M votes were cast in favor and ~420.4K votes were against the merger. Second Sight shareholders also approved a reverse stock split of its common stock as determined by the board in a ratio ranging between 1:2 and 1:10. The stockholders elected each of the six director nominees to the board, among other things. EYES +7.07% to $1.97 premarket July 29

Recent updates

No updates

Second Sight Medical Products, Inc. Competitors

Microbot Medical

Health Catalyst

OptimizeRx

Vivani Medical

View more competitors